Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping

Trial Profile

Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Endostatin (Primary)
  • Indications Neurofibromatoses; Neurofibromatosis 2
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 14 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top